Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function

Update Il y a 4 ans
Reference: NCT00779922

Woman and Man

  • | Country :
  • France
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The purpose of this study is to determine the pharmacokinetic profile of Revlimid® in patients presenting with Multiple Myeloma and impaired renal function, the safety of Revlimid® in the enrolled patients population. and evaluate the efficacy of Revlimid®-Dexamethasone combination in patients presenting MM and impaired renal function at completion of 3 cycles of treatment.


Inclusion criteria

  • Multiple myeloma ,Impaired Renal Function

Links